1. Li M, Li Q, Qu J, Yang H, Lv T, Kong Y*, Zhang H*.The effectiveness of combination therapy with interferon and nucleoside analogs in pediatric patients with chronic hepatitis B: A systematic review and meta-analysis.Hepatology international.2023.17(1).52-62.SCI |
2. Li M#, Wang Y#, Lv T, Liu J, Kong Y, Jia J, Zhao X*.Mapping the incidence of drug-induced liver injury worldwide: a systematic review and meta-analysis.Journal of digestive diseases.2023.24(5).332-339.SCI |
3. Zhao X#, Li M#, Wang H, Xu X, Wu X, Sun Y, Ning C, Wang B, Chen S, You H, Jia J*, Kong Y*.Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China.Journal of clinical and translational hepatology.2022.10(3).420-428.SCI |
4. Chen X#, Li M#, You R, Wang W, Wang Y*.Efficacy and Safety of Ocriplasmin Use for Vitreomacular Adhesion and Its Predictive Factors: A Systematic Review and Meta-Analysis.Frontiers in medicine.2022.8.759311.SCI |
5. Li M, Zhao L, Zhou J, Sun Y, Wu X, Ou X, You H, Kong Y*, Jia J*.Changing clinical care cascade of patients with chronic hepatitis B in Beijing, China.The Lancet regional health Western Pacific.2021.16.100249.SCI |
6. 李敏#, 苏健婷#, 武珊珊, 韦在华, 孔媛媛*, 贾继东*.乙型肝炎肝硬化患者年龄和性别与肝病相关死亡风险的关系.中华肝脏病杂志.2021.29(5).403-408.核心期刊 |
7. Rao Q #, Li M #, Xu W, Pang K, Guo X, Wang D, Liu J, Guo W*, Zhang Z*.Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.Hepatology international.2020.14(5).765-775.SCI |
8. Li M #, Lv T #, Wu S, Wei W, Wu X, Ou X, Ma H, Chow SC, Kong Y*, You H*, Jia J*.Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis.Hepatology international.2020.14(1).105-114.SCI |
9. Li M, Feng L, Li X, Gao R, Wu Y*.Influences of Smoking Status on Effectiveness of Cytochrome P450 Enzyme System Metabolized Medications in Reducing In-Hospital Death in 14 658 Patients With Acute Myocardial Infarction: Data From CPACS-3 Study.Journal of cardiovascular pharmacology and therapeutics.2020.25(5).418-424.SCI |
10. Lv T #, Li M #, Zeng N, Zhang J, Li S, Chen S, Zhang C, Shan S, Duan W, Wang Q, Wu S, You H, Ou X, Ma H, Zhang D, Kong Y*, Jia J*.Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population.Journal of gastroenterology and hepatology.2019.34(10).1676-1684.SCI |
11. Li M #, Kong YY #, Wu SS, Zhou JL, Wu XN, Wang L, Su JT, Ou XJ, You H, Xie XQ, Wei ZH*, Jia JD*.Impact of reimbursement program on liver-related mortality in patients with chronic hepatitis B in Beijing, China.Journal of digestive diseases.2019.20(9).467-475.SCI |
12. 李敏, 单姗, 吴晓宁, 孔媛媛, 欧晓娟, 尤红, 贾继东*.干扰素治疗B、C基因型慢性乙型肝炎临床效果差异的Meta分析.临床肝胆病杂志.2019.35(6).1256-1261.核心期刊 |
13. Li M, Li S, Du X, Wu T, Li X, Ma C, Huo Y, Hu D, Gao R, Wu Y*.Factors Attributed to the Higher In-hospital Mortality of ST Elevation Myocardial Infarction Patients Admitted during Off-hour in Comparison with Those during Regular Hour.PLoS One.2017.12(4).e0175485.SCI |
14. Li M #, Huang Y #, Du X, Li S, Ji J, Patel A, Gao R, Wu Y*. Impact of Prior Use of Four Preventive Medications on Outcomes in Patients Hospitalized for Acute Coronary Syndrome--Results from CPACS-2 Study.PLoS One.2016.11(9).e0163068.SCI |
15. 李敏, 时景璞*.疗效比较研究的方法学应用及其实施过程.中华流行病学杂志.2012.33(11).74-78.核心期刊 |
16. 李敏, 时景璞*, 于慧会.真实世界研究与随机对照试验、单病例随机对照试验在临床治疗性研究中的关系比较.中华流行病学杂志.2012.33(3).342-345.核心期刊 |
17. Jing J #, Li M #, Yuan Y*.Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in cancer: A meta-analysis.Gene.2012.499(2).237-242.SCI |
18. Li M, Shi J*, Fu L, Wang H, Zhou B, Wu X.Genetic polymorphism of MMP family and coronary disease susceptibility: a meta-analysis.Gene.2012.495(1).36-41.SCI |